Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?

Executive Summary

Anthera is exploring strategic alternatives after its lead drug candidate Sollpura failed in Phase III, which means layoffs may be coming soon. Several other biopharma companies have had to turn to job cuts already this year.

Advertisement

Related Content

Vernalis Seeks Buyers, CEO To Step Down, As US Commercial Strategy Disappoints
More US Positions Go As Daiichi Sankyo Refocuses
Jobs Go At Shield Therapeutics As Failed Study Fallout Hits
Hung Out As Axovant Rebuilds Its Pipeline, Expands Focus Beyond Dementia
Eight Clinical Trial Read-Outs To Look Out For In Early 2018
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Achillion Keeps Focus On Complement Factor D Inhibitors As J&J Exits HCV
Anthera jumps 25% on blisibimod update, new endpoint

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100579

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel